Malign Olmayan Hastalıkları Olan Hastalarda Karışık Verici Kimerizmi için Riske Uyarlanmış Allojenik Kök Hücre Nakli

Sade dilde özet

Bu çalışma, riske göre uyarlanmış bir allojenik kök hücre nakli yaklaşımını (Fludarabine, Busulfan, Alemtuzumab gibi ilaçlarla), malign (kötü huylu) olmayan hastalıkları olan hastalarda inceliyor. Çalışmaya, kemik iliği yetmezliği sendromları, bağışıklık yetmezlikleri veya kalıtsal metabolik hastalıkları olan hastalar alınmıştır. Çalışma Faz 2/Faz 3 aşamasında yürütülmüş ve tamamlanmıştır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

PHASE2/PHASE3

Durum

Tamamlandı

Sponsor

Columbia University

Müdahale

Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin

Başlangıç

01.09.2002

Tahmini bitiş

07.09.2021

Ülkeler

United States

İlgili genler

Merkezler

• New York, United States

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria

Patients must meet the eligibility criteria for organ function regardless of diagnosis:

* Age \< 30 or = 30 years of age
* Adequate renal function defined as serum creatinine \< or = 1.5 x normal, or creatinine clearance or radioisotope glomerular filtration rate (GFR) \> or =40 ml/min/m2 or \>60 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range
* Adequate liver function defined as serum glutamic oxaloacetic transaminase (SGOT)(Aspartate transaminase (AST)) or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase (ALT)) \< 5.0 x normal
* Adequate cardiac function defined as shortening fraction of \> or = 28% by echocardiogram, or ejection fraction of \> or = 48% by radionuclide angiogram or echocardiogram
* Adequate pulmonary function defined as asymptomatic or, if symptomatic, carbon monoxide diffusing capacity test (DLCO) \>45% of predicted (corrected for hemoglobin level). If unable to obtain pulmonary function test, O2 saturation \>85% in room air.

Bone Marrow Failure Syndromes

Patients with the following diagnoses are eligible:

Severe Aplastic Anemia:

* Hypocellular bone marrow biopsy (\<25% cellularity) and 2/3 of the following (at diagnosis or nadir):
* Absolute Neutrophil Count (ANC) \<200/mm3,
* Platelets \<20,000/mm3
* Reticulocyte count \<60,000/mm3

Fanconi Anemia:

* Abnormal clastogenic studies (all patients) Severe Congenital Neutropenia (Kostmann's Syndrome) Amegakaryocytic Thrombocytopenia
* Severe thrombocytopenia (\< or =20,000/mm3) at diagnosis
* Severe depletion of megakaryocytes on bone marrow aspirate (\< or =25% normal)

Diamond-Blackfan Anemia:

* Corticosteroid dependent for \> 6 months OR Transfusion dependent OR refractory acquired pure red cell aplasia.

Infantile Osteopetrosis Schwachman-Diamond Syndrome Dyskeratosis Congenita Other bone marrow failure syndromes at discretion of co-principal investigators All BM failure patients must have BM bx within 2 weeks prior to starting therapy to confirm disease status

Immunodeficiencies:

* SCIDS, all subtypes
* Combined Immunodeficiency Syndrome
* Wiskott-Aldrich Syndrome
* Chronic Granulomatous Disease
* Chediak-Higashi Syndrome
* Leukocyte Adhesion Deficiency
* Other immunodeficiencies at discretion of co-principal investigators

Inborn Errors of Metabolism (IEOM):

Transplant is recommended for the following disorders:

* Hurler syndrome (alpha-L-iduronidase deficiency, MPS-I), preferably before age 24 months
* Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency,MPSVI)
* Sly syndrome (beta-glucuronidase deficiency, MPS-VII)
* Globoid cell leukodystrophy (galactocerebrosidase deficiency), with careful attention to neurologic status in the infantile form
* Metachromatic leukodystrophy (arylsulfatase A deficiency),juvenile or adult onset form; late infantile MLD only if pre-symptomatic
* Childhood-onset X-linked adrenoleukodystrophy (X-ALD), at initial signs of neuropsychological deterioration, with dietary modification prior to transplant
* Fucosidosis (fucosidase deficiency)
* Mannosidosis
* Aspartylglucosaminuria
* Niemann-Pick Disease Type B (acid sphingomyelinase deficiency)
* Other diagnoses may be considered at the discretion of the co-principal investigators

Transplant is not recommended for Hunter syndrome (iduronate sulfatase deficiency), Sanfilippo syndrome Type A (heparan N-sulfatase deficiency), Sanfilippo syndrome Type B (-N-acetyl-transferase deficiency), Sanfilippo syndrome Type C (-acetyltransferase deficiency), Sanfilippo syndrome Type D (-acetylglucosamine-6-sulfatase deficiency), Morquio syndrome (galactose-6-sulfatase deficiency); or Niemann-Pick disease Type A or C.

For X-ALD patients greater than 5 years of age, IQ \>80 is required. For other patients greater than 5 years of age, IQ \> 70 is required.

For patients less than 5 years of age, the developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g. mechanical ventilation) would not be predicted to be required in the year following transplantation.

For Gaucher disease (glucocerebrosidase deficiency) Type I (non-neuropathic), the primary therapy is enzyme replacement, but allogeneic stem cell transplant has been used effectively.

Histiocytoses:

* Hemophagocytic Lymphohistiocytosis (HLH)
* Familial Erythrophagocytic Lymphohistiocytosis
* Langerhans Cell Histiocytosis
* Patients with multi-system disease whose initial disease is stable or progressive after minimum 6 weeks of appropriate therapy, OR patients with recurrent multi-system disease.
* Malignant Histiocytosis
* All histiocytic patients must have BM bx within 2 weeks prior to starting therapy to confirm disease status

Other non-malignant diseases not listed above may be eligible if deemed appropriate by the co-principal investigators.